Advertisement

Surgical Intervention for Indeterminate Thyroid Nodules

  • Snehal G. Patel
  • Linwah YipEmail author
Chapter

Abstract

Thyroid nodules are common and have a ~5 % risk of malignancy. On fine-needle aspiration biopsy, nodules classified in one of the three indeterminate Bethesda categories including atypia of undetermined significance/follicular lesion of undetermined significance, follicular neoplasm/suspicious for follicular neoplasm, and suspicious for malignancy have varying rates of malignancy with predicted probabilities of cancer of 5–15 %, 15–30 %, and 60–75 %, respectively. The optimal management of the indeterminate nodule is dependent on cytology category and concern for malignancy and can be further modified by preoperative assessment of clinical, sonographic, and molecular risk factors. Either thyroid lobectomy or total thyroidectomy can provide definitive diagnosis.

Keywords

Thyroid nodules Indeterminate cytology Thyroid cancer Cancer risk factors Indeterminate nodule 

References

  1. 1.
    Harach HR, Franssila KO, Wasenius VM. Occult papillary carcinoma of the thyroid. A “normal” finding in Finland. A systematic autopsy study. Cancer. 1985;56(3):531–8. Epub 1985/08/01. eng.CrossRefPubMedGoogle Scholar
  2. 2.
    Brander A, Viikinkoski P, Nickels J, Kivisaari L. Thyroid gland: US screening in a random adult population. Radiology. 1991;181(3):683–7. Epub 1991/12/01. eng.CrossRefPubMedGoogle Scholar
  3. 3.
    Tan GH, Gharib H. Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern Med. 1997;126(3):226–31. Epub 1997/02/01. eng.CrossRefPubMedGoogle Scholar
  4. 4.
    Frates MC, Benson CB, Charboneau JW, Cibas ES, Clark OH, Coleman BG, et al. Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Radiology. 2005;237(3):794–800. Epub 2005/11/24. eng.CrossRefPubMedGoogle Scholar
  5. 5.
    Mortensen JD, Woolner LB, Bennett WA. Gross and microscopic findings in clinically normal thyroid glands. J Clin Endocrinol Metab. 1955;15(10):1270–80. Epub 1955/10/01. eng.CrossRefPubMedGoogle Scholar
  6. 6.
    Gharib H, Papini E, Paschke R, Duick DS, Valcavi R, Hegedus L, et al. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association Medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: executive summary of recommendations. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinologists. 2010;16(3):468–75. Epub 2010/06/17. eng.Google Scholar
  7. 7.
    Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133. Pubmed Central PMCID: PMC4739132, Epub 2015/10/16. eng.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Bongiovanni M, Spitale A, Faquin WC, Mazzucchelli L, Baloch ZW. The Bethesda system for reporting thyroid cytopathology: a meta-analysis. Acta Cytol. 2012;56(4):333–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Baloch ZW, LiVolsi VA, Asa SL, Rosai J, Merino MJ, Randolph G, et al. Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol. 2008;36(6):425–37.CrossRefPubMedGoogle Scholar
  10. 10.
    Carling T, Udelsman R. Follicular neoplasms of the thyroid: what to recommend. Thyroid Off J Am Thyroid Assoc. 2005;15(6):583–7. Epub 2005/07/21. eng.CrossRefGoogle Scholar
  11. 11.
    Elsheikh TM, Asa SL, Chan JK, DeLellis RA, Heffess CS, LiVolsi VA, et al. Interobserver and intraobserver variation among experts in the diagnosis of thyroid follicular lesions with borderline nuclear features of papillary carcinoma. Am J Clin Pathol. 2008;130(5):736–44.CrossRefPubMedGoogle Scholar
  12. 12.
    Siddiqui MA, Griffith KA, Michael CW, Pu RT. Nodule heterogeneity as shown by size differences between the targeted nodule and the tumor in thyroidectomy specimen: a cause for a false-negative diagnosis of papillary thyroid carcinoma on fine-needle aspiration. Cancer. 2008;114(1):27–33.CrossRefPubMedGoogle Scholar
  13. 13.
    Widder S, Guggisberg K, Khalil M, Pasieka JL. A pathologic re-review of follicular thyroid neoplasms: the impact of changing the threshold for the diagnosis of the follicular variant of papillary thyroid carcinoma. Surgery. 2008;144(1):80–5.CrossRefPubMedGoogle Scholar
  14. 14.
    LiVolsi VA, Baloch ZW. Follicular neoplasms of the thyroid: view, biases, and experiences. Adv Anat Pathol. 2004;11(6):279–87.CrossRefPubMedGoogle Scholar
  15. 15.
    Lloyd RV, Erickson LA, Casey MB, Lam KY, Lohse CM, Asa SL, et al. Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol. 2004;28(10):1336–40.CrossRefPubMedGoogle Scholar
  16. 16.
    Mehanna R, Murphy M, McCarthy J, O’Leary G, Tuthill A, Murphy MS, et al. False negatives in thyroid cytology: impact of large nodule size and follicular variant of papillary carcinoma. Laryngoscope. 2013;123(5):1305–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Kini SR, Miller JM, Hamburger JI. Cytopathology of Hurthle cell lesions of the thyroid gland by fine needle aspiration. Acta Cytol. 1981;25(6):647–52. Epub 1981/11/01. eng.PubMedGoogle Scholar
  18. 18.
    Chen JC, Pace SC, Chen BA, Khiyami A, McHenry CR. Yield of repeat fine-needle aspiration biopsy and rate of malignancy in patients with atypia or follicular lesion of undetermined significance: the impact of the Bethesda System for Reporting Thyroid Cytopathology. Surgery. 2012;152(6):1037–44.CrossRefPubMedGoogle Scholar
  19. 19.
    Sullivan PS, Hirschowitz SL, Fung PC, Apple SK. The impact of atypia/follicular lesion of undetermined significance and repeat fine-needle aspiration: 5 years before and after implementation of the Bethesda System. Cancer Cytopathol. 2014;122(12):866–72.CrossRefPubMedGoogle Scholar
  20. 20.
    Broome JT, Solorzano CC. The impact of atypia/follicular lesion of undetermined significance on the rate of malignancy in thyroid fine-needle aspiration: evaluation of the Bethesda System for Reporting Thyroid Cytopathology. Surgery. 2011;150(6):1234–41.CrossRefPubMedGoogle Scholar
  21. 21.
    Maeda T, Saito M, Otsuki N, Morimoto K, Takahashi M, Iwaki S, et al. Voice quality after surgical treatment for thyroid cancer. Thyroid Off J Am Thyroid Assoc. 2013;23(7):847–53.CrossRefGoogle Scholar
  22. 22.
    Stojadinovic A, Shaha AR, Orlikoff RF, Nissan A, Kornak MF, Singh B, et al. Prospective functional voice assessment in patients undergoing thyroid surgery. Ann Surg. 2002;236(6):823–32. Pubmed Central PMCID: 1422649.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Rosato L, Avenia N, Bernante P, De Palma M, Gulino G, Nasi PG, et al. Complications of thyroid surgery: analysis of a multicentric study on 14,934 patients operated on in Italy over 5 years. World J Surg. 2004;28(3):271–6. Epub 2004/02/13. eng.CrossRefPubMedGoogle Scholar
  24. 24.
    Bergenfelz A, Jansson S, Kristoffersson A, Martensson H, Reihner E, Wallin G, et al. Complications to thyroid surgery: results as reported in a database from a multicenter audit comprising 3,660 patients. Langenbeck’s Arch Surg/Deutsche Gesellschaft fur Chirurgie. 2008;393(5):667–73. Epub 2008/07/18. eng.CrossRefGoogle Scholar
  25. 25.
    Burkey SH, van Heerden JA, Thompson GB, Grant CS, Schleck CD, Farley DR. Reexploration for symptomatic hematomas after cervical exploration. Surgery. 2001;130(6):914–20. Epub 2001/12/14. eng.CrossRefPubMedGoogle Scholar
  26. 26.
    Lang BH, Yih PC, Lo CY. A review of risk factors and timing for postoperative hematoma after thyroidectomy: is outpatient thyroidectomy really safe? World J Surg. 2012;36(10):2497–502. Pubmed Central PMCID: Pmc3465547, Epub 2012/06/21. eng.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Untch BR, Palmer FL, Ganly I, Patel SG, Michael Tuttle R, Shah JP, et al. Oncologic outcomes after completion thyroidectomy for patients with well-differentiated thyroid carcinoma. Ann Surg Oncol. 2014;21(4):1374–8. Epub 2013/12/25. eng.CrossRefPubMedGoogle Scholar
  28. 28.
    Pelizzo MR, Variolo M, Bernardi C, Izuzquiza M, Piotto A, Grassetto G, et al. Complications in thyroid resurgery: a single institutional experience on 233 patients from a whole series of 4,752 homogeneously treated patients. Endocrine. 2014;47(1):100–6.CrossRefPubMedGoogle Scholar
  29. 29.
    Verloop H, Louwerens M, Schoones JW, Kievit J, Smit JW, Dekkers OM. Risk of hypothyroidism following hemithyroidectomy: systematic review and meta-analysis of prognostic studies. J Clin Endocrinol Metab. 2012;97(7):2243–55.CrossRefPubMedGoogle Scholar
  30. 30.
    Stoll SJ, Pitt SC, Liu J, Schaefer S, Sippel RS, Chen H. Thyroid hormone replacement after thyroid lobectomy. Surgery. 2009;146(4):554–8. Pubmed Central PMCID: 2755641, discussion 8–60.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA, Udelsman R. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg. 1998;228(3):320–30. Pubmed Central PMCID: 1191485.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Youngwirth LM, Adam MA, Scheri RP, Roman SA, Sosa JA. Patients treated at low-volume centers have higher rates of incomplete resection and compromised outcomes: analysis of 31,129 patients with papillary thyroid cancer. Ann Surg Oncol. 2016;23(2):403–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Carhill AA, Litofsky DR, Ross DS, Jonklaas J, Cooper DS, Brierley JD, et al. Long-term outcomes following therapy in differentiated thyroid carcinoma: NTCTCS registry analysis 1987–2012. J Clin Endocrinol Metab. 2015;100(9):3270–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Wong KP, Lang BH, Chang YK, Wong KC, Chow FC. Assessing the validity of transcutaneous laryngeal ultrasonography (TLUSG) after thyroidectomy: what factors matter? Ann Surg Oncol. 2015;22(6):1774–80.CrossRefPubMedGoogle Scholar
  35. 35.
    Carneiro-Pla D, Solorzano CC, Wilhelm SM. Impact of vocal cord ultrasonography on endocrine surgery practices. Surgery. 2016;159(1):58–64.CrossRefPubMedGoogle Scholar
  36. 36.
    Baloch ZW, Fleisher S, LiVolsi VA, Gupta PK. Diagnosis of “follicular neoplasm”: a gray zone in thyroid fine-needle aspiration cytology. Diagn Cytopathol. 2002;26(1):41–4. Epub 2002/01/10. eng.CrossRefPubMedGoogle Scholar
  37. 37.
    Trimboli P, Treglia G, Guidobaldi L, Saggiorato E, Nigri G, Crescenzi A, et al. Clinical characteristics as predictors of malignancy in patients with indeterminate thyroid cytology: a meta-analysis. Endocrine. 2014;46(1):52–9. Epub 2013/11/08. eng.CrossRefPubMedGoogle Scholar
  38. 38.
    Sorrenti S, Trimboli P, Catania A, Ulisse S, De Antoni E, D’Armiento M. Comparison of malignancy rate in thyroid nodules with cytology of indeterminate follicular or indeterminate Hurthle cell neoplasm. Thyroid Off J Am Thyroid Assoc. 2009;19(4):355–60. Epub 2009/04/10. eng.CrossRefGoogle Scholar
  39. 39.
    Giorgadze T, Rossi ED, Fadda G, Gupta PK, Livolsi VA, Baloch Z. Does the fine-needle aspiration diagnosis of “Hurthle-cell neoplasm/follicular neoplasm with oncocytic features” denote increased risk of malignancy? Diagn Cytopathol. 2004;31(5):307–12. Epub 2004/10/07. eng.CrossRefPubMedGoogle Scholar
  40. 40.
    Chen H, Nicol TL, Zeiger MA, Dooley WC, Ladenson PW, Cooper DS, et al. Hurthle cell neoplasms of the thyroid: are there factors predictive of malignancy? Ann Surg. 1998;227(4):542–6. Pubmed Central PMCID: 1191310.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Nayar R, Ivanovic M. The indeterminate thyroid fine-needle aspiration: experience from an academic center using terminology similar to that proposed in the 2007 National Cancer Institute Thyroid Fine Needle Aspiration State of the Science Conference. Cancer. 2009;117(3):195–202.PubMedGoogle Scholar
  42. 42.
    Banks ND, Kowalski J, Tsai HL, Somervell H, Tufano R, Dackiw AP, et al. A diagnostic predictor model for indeterminate or suspicious thyroid FNA samples. Thyroid Off J Am Thyroid Assoc. 2008;18(9):933–41.CrossRefGoogle Scholar
  43. 43.
    Sclabas GM, Staerkel GA, Shapiro SE, Fornage BD, Sherman SI, Vassillopoulou-Sellin R, et al. Fine-needle aspiration of the thyroid and correlation with histopathology in a contemporary series of 240 patients. Am J Surg. 2003;186(6):702–9; discussion 9–10. Epub 2003/12/16. eng.CrossRefPubMedGoogle Scholar
  44. 44.
    Smith M, Pantanowitz L, Khalbuss WE, Benkovich VA, Monaco SE. Indeterminate pediatric thyroid fine needle aspirations: a study of 68 cases. Acta Cytol. 2013;57(4):341–8.CrossRefPubMedGoogle Scholar
  45. 45.
    Norlen O, Charlton A, Sarkis LM, Henwood T, Shun A, Gill AJ, et al. Risk of malignancy for each Bethesda class in pediatric thyroid nodules. J Pediatr Surg. 2015;50(7):1147–9. Epub 2015/03/19. eng.CrossRefPubMedGoogle Scholar
  46. 46.
    Francis GL, Waguespack SG, Bauer AJ, Angelos P, Benvenga S, Cerutti JM, et al. Management guidelines for children with thyroid nodules and differentiated thyroid cancer. Thyroid Off J Am Thyroid Assoc. 2015;25(7):716–59.CrossRefGoogle Scholar
  47. 47.
    Kamran SC, Marqusee E, Kim MI, Frates MC, Ritner J, Peters H, et al. Thyroid nodule size and prediction of cancer. J Clin Endocrinol Metab. 2013;98(2):564–70.CrossRefPubMedGoogle Scholar
  48. 48.
    Tuttle RM, Lemar H, Burch HB. Clinical features associated with an increased risk of thyroid malignancy in patients with follicular neoplasia by fine-needle aspiration. Thyroid Off J Am Thyroid Assoc. 1998;8(5):377–83. Epub 1998/06/12. eng.CrossRefGoogle Scholar
  49. 49.
    Zhang YW, Greenblatt DY, Repplinger D, Bargren A, Adler JT, Sippel RS, et al. Older age and larger tumor size predict malignancy in hurthle cell neoplasms of the thyroid. Ann Surg Oncol. 2008;15(10):2842–6.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Nam IC, Choi H, Kim ES, Mo EY, Park YH, Sun DI. Characteristics of thyroid nodules causing globus symptoms. Eur Arch otorhinolaryngol Off J Eur Fed Otorhinolaryngol Soc (EUFOS) Affiliated Ger Soc Otorhinolaryngology – Head Neck Surg. 2015;272(5):1181–8. Epub 2015/02/01. eng.Google Scholar
  51. 51.
    Kwak JY, Jung I, Baek JH, Baek SM, Choi N, Choi YJ, et al. Image reporting and characterization system for ultrasound features of thyroid nodules: multicentric Korean retrospective study. Korean J Radiol. 2013;14(1):110–7. Pubmed Central PMCID: Pmc3542293, Epub 2013/01/17. eng.CrossRefPubMedGoogle Scholar
  52. 52.
    Mendez W, Rodgers SE, Lew JI, Montano R, Solorzano CC. Role of surgeon-performed ultrasound in predicting malignancy in patients with indeterminate thyroid nodules. Ann Surg Oncol. 2008;15(9):2487–92.CrossRefPubMedGoogle Scholar
  53. 53.
    Khoncarly SM, Tamarkin SW, McHenry CR. Can ultrasound be used to predict malignancy in patients with a thyroid nodule and an indeterminate fine-needle aspiration biopsy? Surgery. 2014;156(4):967–70. Epub 2014/07/31. eng.CrossRefPubMedGoogle Scholar
  54. 54.
    Rago T, Di Coscio G, Basolo F, Scutari M, Elisei R, Berti P, et al. Combined clinical, thyroid ultrasound and cytological features help to predict thyroid malignancy in follicular and Hupsilonrthle cell thyroid lesions: results from a series of 505 consecutive patients. Clin Endocrinol (Oxf). 2007;66(1):13–20. Epub 2007/01/05. eng.Google Scholar
  55. 55.
    Brito JP, Gionfriddo MR, Al Nofal A, Boehmer KR, Leppin AL, Reading C, et al. The accuracy of thyroid nodule ultrasound to predict thyroid cancer: systematic review and meta-analysis. J Clin Endocrinol Metab. 2014;99(4):1253–63. Pubmed Central PMCID: Pmc3973781, Epub 2013/11/28. eng.CrossRefPubMedGoogle Scholar
  56. 56.
    LiVolsi VA, Asa SL. The demise of follicular carcinoma of the thyroid gland. Thyroid Off J Am Thyroid Assoc. 1994;4(2):233–6. Epub 1994/01/01. eng.CrossRefGoogle Scholar
  57. 57.
    Vriens D, de Wilt JH, van der Wilt GJ, Netea-Maier RT, Oyen WJ, de Geus-Oei LF. The role of [18F]-2-fluoro-2-deoxy-d-glucose-positron emission tomography in thyroid nodules with indeterminate fine-needle aspiration biopsy: systematic review and meta-analysis of the literature. Cancer. 2011;117(20):4582–94. Epub 2011/03/25. eng.CrossRefPubMedGoogle Scholar
  58. 58.
    Vriens D, Adang EM, Netea-Maier RT, Smit JW, de Wilt JH, Oyen WJ, et al. Cost-effectiveness of FDG-PET/CT for cytologically indeterminate thyroid nodules: a decision analytic approach. J Clin Endocrinol Metab. 2014;99(9):3263–74. Epub 2014/05/31. eng.CrossRefPubMedGoogle Scholar
  59. 59.
    Lippolis PV, Tognini S, Materazzi G, Polini A, Mancini R, Ambrosini CE, et al. Is elastography actually useful in the presurgical selection of thyroid nodules with indeterminate cytology? J Clin Endocrinol Metab. 2011;96(11):E1826–30. Epub 2011/08/26. eng.CrossRefPubMedGoogle Scholar
  60. 60.
    Trimboli P, Treglia G, Sadeghi R, Romanelli F, Giovanella L. Reliability of real-time elastography to diagnose thyroid nodules previously read at FNAC as indeterminate: a meta-analysis. Endocrine. 2015;50(2):335–43. Epub 2014/12/24. eng.CrossRefPubMedGoogle Scholar
  61. 61.
    de Matos LL, Del Giglio AB, Matsubayashi CO, de Lima FM, Del Giglio A, da Silva Pinhal MA. Expression of CK-19, galectin-3 and HBME-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis. Diagn Pathol. 2012;7:97. Pubmed Central PMCID: 3523001.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Bartolazzi A, Orlandi F, Saggiorato E, Volante M, Arecco F, Rossetto R, et al. Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Lancet Oncol. 2008;9(6):543–9.CrossRefPubMedGoogle Scholar
  63. 63.
    Lee EK, Chung KW, Min HS, Kim TS, Kim TH, Ryu JS, et al. Preoperative serum thyroglobulin as a useful predictive marker to differentiate follicular thyroid cancer from benign nodules in indeterminate nodules. J Korean Med Sci. 2012;27(9):1014–8. Pubmed Central PMCID: Pmc3429817, Epub 2012/09/13. eng.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D, Diggans J, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med. 2012;367(8):705–15.CrossRefPubMedGoogle Scholar
  65. 65.
    Marti JL, Avadhani V, Donatelli LA, Niyogi S, Wang B, Wong RJ, et al. Wide inter-institutional variation in performance of a molecular classifier for indeterminate thyroid nodules. Ann Surg Oncol. 2015;22(12):3996–4001.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Ferris RL, Baloch Z, Bernet V, Chen A, Fahey 3rd TJ, Ganly I, et al. American thyroid association statement on surgical application of molecular profiling for thyroid nodules: current impact on perioperative decision making. Thyroid Off J Am Thyroid Assoc. 2015;25(7):760–8. Pubmed Central PMCID: 4519104.CrossRefGoogle Scholar
  67. 67.
    Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet. 2013;381(9871):1058–69. Pubmed Central PMCID: 3931461.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Nikiforov YE, Yip L, Nikiforova MN. New strategies in diagnosing cancer in thyroid nodules: impact of molecular markers. Clin Cancer Res Off J Am Assoc Cancer Res. 2013;19(9):2283–8.CrossRefGoogle Scholar
  69. 69.
    Fnais N, Soobiah C, Al-Qahtani K, Hamid JS, Perrier L, Straus SE, et al. Diagnostic value of fine needle aspiration BRAF(V600E) mutation analysis in papillary thyroid cancer: a systematic review and meta-analysis. Hum Pathol. 2015;46(10):1443–54.CrossRefPubMedGoogle Scholar
  70. 70.
    Nikiforov YE, Ohori NP, Hodak SP, Carty SE, LeBeau SO, Ferris RL, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab. 2011;96(11):3390–7. Pubmed Central PMCID: 3205883.CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Yip L, Wharry LI, Armstrong MJ, Silbermann A, McCoy KL, Stang MT, et al. A clinical algorithm for fine-needle aspiration molecular testing effectively guides the appropriate extent of initial thyroidectomy. Ann Surg. 2014;260(1):163–8.CrossRefPubMedGoogle Scholar
  72. 72.
    Nikiforov YE, Carty SE, Chiosea SI, Coyne C, Duvvuri U, Ferris RL, et al. Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. Cancer. 2014;120(23):3627–34.CrossRefPubMedGoogle Scholar
  73. 73.
    Nikiforov YE, Carty SE, Chiosea SI, Coyne C, Duvvuri U, Ferris RL, et al. Impact of the multi-gene ThyroSeq next-generation sequencing assay on cancer diagnosis in thyroid nodules with atypia of undetermined significance/follicular lesion of undetermined significance cytology. Thyroid Off J Am Thyroid Assoc. 2015;25:1217–23.CrossRefGoogle Scholar
  74. 74.
    Labourier E, Shifrin A, Busseniers AE, Lupo MA, Manganelli ML, Andruss B, et al. Molecular testing for miRNA, mRNA, and DNA on fine-needle aspiration improves the preoperative diagnosis of thyroid nodules with indeterminate cytology. J Clin Endocrinol Metab. 2015;100(7):2743–50. Pubmed Central PMCID: 4490308.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Tufano RP, Teixeira GV, Bishop J, Carson KA, Xing M. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine. 2012;91(5):274–86.CrossRefPubMedGoogle Scholar
  76. 76.
    Aragon Han P, Kim HS, Cho S, Fazeli R, Najafian A, Khawaja H, et al. Association of BRAF mutation and MicroRNA expression with central lymph node metastases in papillary thyroid cancer: a prospective study from four endocrine surgery centers. Thyroid Off J Am Thyroid Assoc. 2016;26(4):532–42.CrossRefGoogle Scholar
  77. 77.
    Gouveia C, Can NT, Bostrom A, Grenert JP, van Zante A, Orloff LA. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the university of California, San Francisco, experience. JAMA Otolaryngol Head Neck Surg. 2013;139(11):1164–70.CrossRefPubMedGoogle Scholar
  78. 78.
    Yip L, Nikiforova MN, Yoo JY, McCoy KL, Stang MT, Armstrong MJ, et al. Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients. Ann Surg. 2015;262(3):519–25; discussion 24–5.CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Melo M, da Rocha AG, Vinagre J, Batista R, Peixoto J, Tavares C, et al. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab. 2014;99(5):E754–65. Pubmed Central PMCID: 4191548.CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Nikiforova MN, Wald AI, Roy S, Durso MB, Nikiforov YE. Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J Clin Endocrinol Metab. 2013;98(11):E1852–60. Pubmed Central PMCID: 3816258, Epub August 26, 2013.CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Hyeon J, Ahn S, Shin JH, Oh YL. The prediction of malignant risk in the category “atypia of undetermined significance/follicular lesion of undetermined significance” of the Bethesda System for Reporting Thyroid Cytopathology using subcategorization and BRAF mutation results. Cancer Cytopathol. 2014;122(5):368–76.CrossRefPubMedGoogle Scholar
  82. 82.
    Network NCC. Thyroid Carcinoma (Version 2.2015). Available from: http://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf.

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  1. 1.Department of Surgery, Division of Endocrine Surgery and Surgical OncologyUniversity of PittsburghPittsburghUSA
  2. 2.University of Pittsburgh School of MedicinePittsburghUSA

Personalised recommendations